imiquimod has been researched along with pf 3512676 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Amlie-Lefond, C; Connelly, MP; Dunn, KS; Huffnagle, GB; Paz, DA; Whelan, HT; Whelan, NT | 1 |
| Agarwal, K; Landrigan, A; Utz, PJ; Yiu, G | 1 |
1 review(s) available for imiquimod and pf 3512676
| Article | Year |
|---|---|
Innate immunity for biodefense: a strategy whose time has come.
Topics: Aminoquinolines; Animals; Humans; Imidazoles; Imiquimod; Immunity, Innate; Oligodeoxyribonucleotides; Toll-Like Receptor 4; Toll-Like Receptor 9 | 2005 |
1 other study(ies) available for imiquimod and pf 3512676
| Article | Year |
|---|---|
Therapeutic Toll-like receptor agonists directly influence mouse and human T cell lymphoma cell viability and cytokine secretion.
Topics: Aminoquinolines; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Chemokine CCL5; Cytokines; Dose-Response Relationship, Drug; Humans; Imiquimod; Interleukin-10; Lymphoma, T-Cell; Mice; Oligodeoxyribonucleotides; Time Factors; Toll-Like Receptors | 2012 |